Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

被引：3
|
作者：
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Maruyama, Dai
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan
[5] Kyoto Prefectural Univ Med, Univ Hosp, Div Hematol & Oncol, Kyoto, Japan
[6] Tokai Univ, Dept Hematol & Oncol, Isehara, Kanagawa, Japan
[7] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e19018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19018
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2018, 131 (11) : 1183 - 1194
  • [2] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [3] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes, Anas
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlett, Nancy L.
    Cheson, Bruce D.
    de Vos, Sven
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Chen, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
  • [4] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [5] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
  • [6] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Bartlett, Nancy L.
    Ramchandren, Radhakrishnan
    Vose, Julie M.
    Moskowitz, Alison J.
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Kato, Kazunobu
    Fong, Abraham
    Advani, Ranjana H.
    BLOOD, 2016, 128 (22)
  • [7] Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Hatake, Kiyohiko
    Kinoshita, Tomohiro
    Fukuhara, Noriko
    Choi, Ilseung
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Terui, Yasuhito
    Higuchi, Yusuke
    Onishi, Yasushi
    Abe, Yasunobu
    Kobayashi, Tsutomu
    Shirasugi, Yukari
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (05) : 1007 - 1012
  • [8] Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Zhang, Chiyu
    Taft, David
    Ansari, Sahar
    Sacchi, Mariana
    Ho, Linda
    Herrera, Alex F.
    BLOOD, 2021, 138 (06) : 427 - 438
  • [9] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
    Kaleka, Guneet
    Moskoff, Benjamin
    Zafar, Aneeqa
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Hoeg, Rasmus T.
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6318 - 6319
  • [10] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Terui, Yasuhito
    Yamamoto, Kazuhito
    Fukuhara, Noriko
    Choi, Ilseung
    Kuroda, Junya
    Ando, Kiyoshi
    Hattori, Akira
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
12345